[ivory-search id="184" title="Recordati AJAX Search Form"]

Media

  • Business & Financial News
    2024, May 16

    THE WINNER OF THE 11TH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI ANNOUNCED

    2024-05-13 13:14

    RECORDATI: PUBLICATION OF DOCUMENTS

    2024-05-09 17:04

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS

    2024-05-09 13:03

    THE STRONG PERFORMANCE OF THE GROUP CONTINUES IN THE FIRST QUARTER OF 2024: REVENUE +10.2%, EBITDA +10.5%, ADJUSTED NET INCOME +5.6%

    2024-04-24 19:18

    RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 22.04.2024

    2024, April 23

    Press release (on "il Sole 24 Ore") - 2023 final payment dividend

    2024-04-22 13:22

    RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2023 FINANCIAL STATEMENTS AND THE DIVIDEND OF € 1.20 PER SHARE (+4.3% vs 2022)

    2024-04-11 19:15

    RECORDATI: CONCLUSION OF THE SHARE BUY-BACK PROGRAM INITIATED ON 2nd OCTOBER 2023.

    2024, March 29

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance Report 2023

    2024-03-28 17:32

    RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024

    2024-03-22 19:43

    RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024

    2024, March 20

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 22.04.2024

    2024-03-19 12:25

    RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)

    2024-02-22 12:45

    FY 2023 PRELIMINARY RESULTS AT TOP END OF GUIDANCE: REVENUE +12.4%, EBITDA +14.4%, ADJUSTED NET INCOME +10.8%. FY 2024 TARGETS REFLECT CONTINUED GROWTH ACROSS ALL KEY METRICS

    2024-01-29 18:04

    RECORDATI: 2024 CORPORATE EVENTS’ CALENDAR

    2023, November 8

    Press release (on "il Sole 24 Ore") - 2023 Interim Dividend Payment

    2023-11-07 12:33

    FIRST NINE MONTHS 2023 AHEAD OF PLAN: REVENUE +13.0%, EBITDA +15.4%, ADJUSTED NET INCOME +14.2%. 2025 REVENUE AND PROFITS EXPECTED TO EXCEED TARGETS SET IN FEBRUARY 2023

    2023, October 16

    RECORDATI APPOINTS MILAN ZDRAVKOVIC AS EXECUTIVE VICE PRESIDENT R&D

    2023-09-29 18:03

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS

    2023, August 1

    Press release (on il Sole 24 Ore) - Interim Report First Half 2023

    2023, July 31

    RECORDATI: PUBLIC DISCLOSURE - INTERIM FINANCIAL STATEMENTS

    2023-07-28 12:43

    FIRST HALF 2023 RESULTS CONFIRM STRONG MOMENTUM OF THE GROUP: REVENUE +17.0%, EBITDA +21.3%, ADJUSTED NET INCOME +27.9%. RECENT TRANSACTION WITH GSK FURTHER STRENGTHENS SPC UROLOGY FRANCHISE

    2023-07-20 17:48

    RECORDATI: AGREEMENT FOR THE DISTRIBUTION OF AVODART® AND COMBODART® IN EUROPE

    2023-06-27 18:11

    RECORDATI: PERFORMANCE SHARE PLAN 2023-2025 ASSIGNMENT OF RIGHTS PROVIDED UNDER THE FIRST CYCLE

    2023, May 19

    LAUNCH OF THE 11TH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH

    2023-05-17 11:53

    RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023-05-11 13:48

    FIRST QUARTER 2023 RESULTS: REVENUE +31.5%, EBITDA(1) +35.4%, ADJUSTED NET INCOME(2) +33.3%. FY 2023 GUIDANCE REVISED UPWARDS

    2023, April 22

    Press release (on "il Sole 24 Ore") - 2022 final payment dividend

    2023, April 21

    RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023-04-21 17:12

    RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023, March 31

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2022,

    2023-03-21 16:14

    RECORDATI: PUBLICATION OF THE SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY PUBLICATION OF SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS

    2023-03-30 13:37

    RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023-03-27 19:09

    RECORDATI: FILING OF A SOLE SLATE FOR THE RENEWAL OF THE BOARD OF STATUTORY AUDITORS – EXTENSION OF THE DEADLINE AND REDUCTION BY HALF OF THE PARTICIPATION REQUIREMENTS FOR THE FILING

    2023-03-22 18:23

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023)

    2023-03-16 12:34

    RECORDATI BOARD APPROVES THE 2022 ACCOUNTS, CONFIRMING STRONG CONSOLIDATED FINANCIAL RESULTS: REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2022 DIVIDEND € 1.15 (+4.5%),

    2023, March 11

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 21.04.2023,

    2023-03-10 12:53

    RECORDATI: ORDINARY GENERAL MEETING OF SHAREHOLDERS CONVENED FOR 21 APRIL 2023, IN A SINGLE CALL. DOCUMENTS RELATING TO THE GENERAL MEETING.,

    2023-02-21 12:59

    RECORDATI: STRONG PRELIMINARY 2022 FINANCIAL RESULTS. REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2023-2025 THREE-YEAR PLAN APPROVED; 2025 REVENUE TARGET BETWEEN € 2,250 AND € 2,350 MILLION,

    2023-01-16 18:09

    RECORDATI: 2023 CORPORATE EVENTS’ CALENDAR,

    2022, November 9

    Press release (on "il Sole 24 Ore") - 2022 Interim Dividend Payment,

    2022-11-08 13:01

    RECORDATI: RESULTS OF FIRST NINE MONTHS OF 2022 AHEAD OF EXPECTATIONS. REVENUE +19.1%, EBITDA(1) +15.2% AND ADJUSTED NET INCOME(2) +13.5%. FY 2022 RESULTS GUIDANCE REVISED UPWARDS,

    2022, August 2

    Press release (on il Sole 24 Ore) - Interim Report First Half 2022,

    2022-08-02 18:06

    RECORDATI: PUBLIC DISCLOSURE

    2022-08-01 14:31

    RECORDATI: PUBLIC DISCLOSURE

    2022-07-28 13:28

    RECORDATI FIRST HALF 2022 RESULTS: REVENUE +15.8%, EBITDA +11.5%, ADJUSTED NET INCOME +7.1%.,

    2022-06-20 07:33

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2022, May 23

    THE TENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI COMES TO END,

    2022-05-13 17:09

    RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022

    2022-05-10 11:56

    RECORDATI: FIRST QUARTER 2022 RESULTS APPROVED, REVENUE +9.0%, EBITDA +8.7%. 2022 TARGETS CONFIRMED,

    2022-05-03 12:45

    RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022

    2022, April 30

    Press release (on "il Sole 24 Ore") - 2021 final payment dividend,

    2022-04-29 12:44

    RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2021 FINANCIAL STATEMENTS. DIVIDEND OF € 1.10 PER SHARE (+4.8% vs 2020). THE NEW BOARD OF DIRECTORS HAS BEEN APPOINTED,

    2022-04-08 16:52

    RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.,

    2022-04-08 16:52

    RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.

    2022, April 2

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2021,

    2022-04-01 17:34

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)

    2022, March 19

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2022,

    2022-03-18 16:18

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)

    2022-03-17 17:44

    RECORDATI: BOARD APPROVES THE 2021 ACCOUNTS. SALES € 1,580.1 MILLION (+9.1%), EBITDA(1) € 602.3 MILLION (+5.8%) ADJUSTED NET INCOME € 386.0 MILLION (+8.7%). 2021 DIVIDEND € 1.10 (+4.8%),

    2022-03-16 18:03

    RECORDATI COMPLETES THE ACQUISITION OF EUSA PHARMA (UK),

    2022-02-24 13:18

    RECORDATI: PRELIMINARY 2021 RESULTS IN LINE WITH TARGETS REVENUE +9.1%, EBITDA +5.8%, NET INCOME +8.7%,

    2021-12-16 13:52

    RECORDATI: KIM STRATTON CO-OPTED TO THE BOARD OF DIRECTORS AS A NON-EXECUTIVE AND NON-INDEPENDENT DIRECTOR,

    2021-12-03 07:32

    RECORDATI TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND NICHE ONCOLOGY DISEASES,

    2021-12-01 10:09

    RECORDATI: ANDREA RECORDATI APPOINTED CHAIRMAN AND ROBERT KOREMANS APPOINTED CHIEF EXECUTIVE OFFICER,

    2021-10-29 18:27

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS RECORDATI SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2021, October 29

    Press release (on "il Sole 24 Ore") - 2021 Interim Dividend Payment,

    2021-10-28 13:22

    RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES,

    2021-10-11 19:11

    RECORDATI: RESIGNATION OF A NON-EXECUTIVE DIRECTOR,

    2021-10-11 12:24

    RECORDATI: 2022 CORPORATE EVENTS’ CALENDAR,

    2021, July 30

    Press release (on "il Sole 24 Ore") - Interim Report First Half 2021,

    2022-07-30 15:50

    RECORDATI: PUBLIC DISCLOSURE

    2021-07-29 12:04

    RECORDATI: FIRST HALF OF 2021 RESULTS APPROVED, REVENUE +1.4%, EBITDA -3.4%, NET INCOME +5.2%. RETURN TO GROWTH IN THE SECOND QUARTER,

    2021-07-16 07:31

    RECORDATI: Rob Koremans new Chief Executive Officer effective 1 December 2021, Andrea Recordati to be appointed as Chairman.,

    2021, July 14

    RECORDATI SUPPORTS THE FORESTAMI PROJECT,

    2021-07-09 07:50

    STRENGTHENING OF THE CORPORATE GOVERNANCE,

    2021-05-05 17:17

    RECORDATI: PUBLIC DISCLOSURE (MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021, May 25

    THE TENTH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH HAS ANNOUNCED THE CALL FOR APPLICATIONS,

    2021-05-06 13:12

    RECORDATI: FIRST QUARTER 2021 RESULTS AND 2021-2023 THREE-YEAR PLAN APPROVED; 2023 REVENUE FORECAST BETWEEN €1,900 AND € 2,000 MILLION,

    2021-04-28 09:37

    RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE,

    2021-03-23 00:00

    RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE,

    2021-04-22 12:22

    RECORDATI: REGISTRATION WITH THE COMPANIES’ REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED,

    2021-04-22 11:25

    RECORDATI: PUBLIC DISCLOSURE (SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021, April 21

    Press release (on "il Sole 24 Ore") - 2020 final payment dividend,

    2021-04-20 12:47

    RECORDATI: SHAREHOLDERS APPROVE THE 2020 ACCOUNTS. DIVIDEND € 1.05 PER SHARE (+5.0% vs 2019).,

    2021-04-12 18:13

    RECORDATI: THE MERGER DEED RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. HAS BEEN EXECUTED,

    2021, March 30

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2020,

    2021-03-29 18:12

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021, March 25

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 20.04.2021)

    2021, March 24

    RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN JAPAN,

    2021, March 20

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 20.04.2021,

    2021-03-19 18:59

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021-03-18 16:42

    RECORDATI: BOARD APPROVES THE 2020 ACCOUNTS. SALES € 1,448.9 MILLION (-2.2%), EBITDA € 569.3 MILLION (+4.7%) ADJUSTED NET INCOME € 410.4 MILLION (+7.3%). 2020 DIVIDEND € 1.05 (+ 5.0 %),

    2021-02-22 18:25

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2021-02-22 12:58

    RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING AND NET INCOME. EBITDA +4.7% AND ADJ NET INCOME +7.3%,

    2021-01-29 18:06

    RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES,

    2021, January 26

    RECORDATI: CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia

    2020-12-29 11:10

    Public disclosure

    2020-12-18 12:41

    Public disclosure

    2020-12-17 18:04

    RECORDATI: MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. APPROVED BY THE EXTRAORDINARY SHAREHOLDERS’ MEETING,

    2020-12-09 18:04

    RECORDATI: TAX PETITION FOR THE FRUITION OF ACE TAX BENEFITS DERIVING FROM THE REVERSE MERGER OBTAINED POSITIVE ANSWER,

    2020-11-30 18:04

    RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY,

    2021-11-30 00:00

    RECORDATI: 2021 CORPORATE EVENTS’ CALENDAR,

    2020, November 14

    Press release - (on "Milano Finanza") - Extract of the call notice of the extraordinary general meeting of the shareholders 17.12.2020,

    2020-11-13 17:42

    Call to an extraordinary general meeting of the shareholders 17.12.2020 (Reverse Merger),

    2021-03-25 15:04

    RECORDATI: PUBLICATION OF DOCUMENTATION RELATED TO THE REVERSE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.

    2020, October 30

    Press release (on "il Sole 24 Ore") - 2020 Interim Dividend Payment,

    2020-10-29 13:11

    RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%,

    2020-10-07 15:15

    RECORDATI: PUBLICATION OF THE INFORMATION DOCUMENT RELATING TO MAJOR TRANSACTIONS WITH RELATED PARTIES

    2021-05-25 15:04

    RECORDATI: FILING OF THE MERGER PLAN RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.

    2020-10-01 18:07

    RECORDATI: RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED,

    2020-09-21 00:00

    RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION,

    2020-08-25 00:00

    RECORDATI: U.S. FDA APPROVES CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A NEW PRACTICAL TREATMENT OPTION FOR THE OCULAR MANIFESTATIONS OF CYSTINOSIS,

    2020-08-03 17:06

    Public disclosure compliance

    2020, July 31

    Press release (on "il Sole 24 Ore") - Interim Report First Half 2020,

    2020-07-30 13:53

    RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%,

    2020-07-17 13:53

    ISTURISA® IS NOW AVAILABLE AS A MEDICAL TREATMENT FOR CUSHING'S SYNDROME IN GERMANY,

    2020-06-17 13:52

    RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE,

    2020, June 2

    Recordati Rare Diseases announces first European launch of Isturisa® (osilodrostat),

    2020-05-27 12:30

    Public disclosure

    2020, May 27

    RECORDATI RARE DISEASES INC. ANNOUNCES AVALABILITY OF ISTURISA® (OSILODROSTAT) IN THE UNITED STATES,

    2020-05-07 12:35

    RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%,

    2020, April 30

    Press release (on "il Sole 24 Ore") - 2019 final payment dividend,

    2020-04-03 17:50

    Public disclosure

    2020-04-29 12:11

    RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018),

    2020-04-17 18:15

    RECORDATI: PROPOSAL OF CANDIDATES FOR THE OFFICE OF DIRECTORS AND THEIR RELATIVE REMUNERATION PRESENTED BY THE MAJORITY SHAREHOLDER FIMEI SpA IN RELATION TO ITEM 2 ON THE SHAREHOLDERS’ MEETING AGENDA

    2020-04-08 10:46

    Public disclosure

    2020-04-08 18:54

    RECORDATI: PUBLICATION OF THE LIST OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY

    2020, April 8

    Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome,

    2020-04-04 18:28

    RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS

    2020-03-30 12:24

    Public disclosure

    2020, March 26

    RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN,

    2020, March 25

    Press release (on "il Sole 24 Ore") - 2019 financial statements and corporate governance report,

    2020-03-24 17:36

    Public Disclosure

    2020, March 20

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2020,

    2020-03-19 17:56

    Public disclosure

    2020-03-18 14:11

    BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).,

    2020, March 18

    RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19,

    2020-03-12 19:59

    RECORDATI: LAUNCH OF A NEW SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2020-03-09 08:32

    RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN THE U.S.,

    2020-02-17 19:29

    RECORDATI: LAUNCH OF A SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2020-02-14 14:04

    RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%.,

    2020, February 4

    RECORDATI: CHANGE IN 2020 CORPORATE EVENTS’ CALENDAR,

    2020-01-15 12:01

    RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED,

    2019-11-15 17:24

    RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT),

    2019, November 12

    RECORDATI: 2020 CORPORATE EVENTS' CALENDAR,

    2019, November 1

    Press release - 2019 Interim dividend payment,

    2019-10-31 12:58

    RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%).,

    2019, October 29

    INAUGURAZIONE DEL PADIGLIONE GIOVANNI RECORDATI ALL'OSPEDALE DEI BAMBINI VITTORE BUZZI,

    2019-10-23 12:03

    RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED,

    2019, September 5

    ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO ALBERTO AURICCHIO,

    2019-07-31 19:15

    Public disclosure compliance

    2019, July 31

    Sole24Ore - Notice Interim Report First Half 2019,

    2019-07-30 13:10

    RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA +7.4%, NET INCOME +6.1%,

    2019-07-12 20:15

    RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699),

    2019, June 24

    RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS,

    2019-05-08 12:24

    RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED,

    2019-05-03 16:47

    Public Disclosure Compliance

    2019-04-15 19:07

    Public Disclosure Compliance

    2019-04-15 09:06

    RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY,

    2019, April 12

    Press Release - Notice on 2018 final payment dividend,

    2019-04-11 14:38

    RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017),

    2019-03-20 18:57

    Public Disclosure

    2019-03-12 18:23

    Public Disclosure

    2019-03-08 10:45

    Public Disclosure

    2019, March 5

    Press release - Notice of filing of 2018 Annual Report and Corporate Governance,

    2019-03-05 19:23

    Public Disclosure

    2019, March 5

    Sole24Ore - Extract of the call notice of the Ordinary Shareholders meeting - 11.04.2019,

    2019-03-04 18:18

    Public Disclosure

    2019-02-28 15:08

    RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%),

    2019-02-11 12:54

    RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%.,

    2019, February 6

    Public Disclosure Compliance

    2019, February 6

    RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN,

    2019, February 5

    RECORDATI: SHAREHOLDERS APPOINT THE NEW BOARD OF DIRECTORS. THE BOARD OF DIRECTORS APPOINTS FLEMMING ØRNSKOV AS CHAIRMAN AND CONFIRMS ANDREA RECORDATI AS CHIEF EXECUTIVE OFFICER,

    2019, February 1

    RECORDATI: TERMINATION BY MUTUAL AGREEMENT OF THE EMPLOYMENT RELATIONSHIP WITH ALBERTO RECORDATI

    2019, January 28

    RECORDATI: 2019 CORPORATE EVENTS' CALENDAR,

    2019-01-11 17:30

    RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY A GROUP OF ASSET MANAGEMENT COMPANIES AND INSTITUTIONAL INVESTORS

    2019-01-07 14:54

    RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY FIMEI S.P.A

    2019, January 7

    Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate

    2019, January 7

    Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate

    2018, December 31

    RECORDATI CLOSES ACQUISITION OF TONIPHARM S.A.S. IN FRANCE

    2018-12-21 16:38

    RECORDATI: EXPECTATIONS FOR 2018 CONFIRMED AND 2019 OBJECTIVES ANNOUNCED; APPROVAL OF THE ISSUER’S NOTICE PURSUANT TO ART. 103 PARA. 3 OF ITALIAN LEGISLATIVE DECREE 58/1998, WITH REFERENCE TO THE PUBLIC MANDATORY TENDER OFFER FOR THE TOTAL NUMBER OF ORDINARY SHARES OF RECORDATI S.P.A.

    2018, December 21

    RECORDATI ACQUIRES TONIPHARM S.A.S. IN FRANCE

    2018, December 20

    Sole24Ore: Call notice of the Ordinary Shareholders Meeting 5 February 2019,

    2018, December 20

    RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®

    2018-12-19 19:41

    Public Disclosure

    2018-12-12 20:13

    Shareholders Agreements

    2018-12-11 19:18

    Publication of the abstract of the Shareholders' Agreements

    2018-12-06 18:01

    RECORDATI: RESIGNATION OF BOARD MEMBERS; CO-OPTION OF THREE NEW DIRECTORS; APPOINTMENT OF CHAIRMAN; AN ORDINARY GENERAL MEETING OF THE SHAREHOLDERS IS CONVENED TO APPOINT A NEW BOARD OF DIRECTORS

    2018, December 5

    RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR NEUROTROPHIC KERATITIS

    2018, November 5

    RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR MSUD

    2018, October 31

    Notice: 2018 interim dividend payment,

    2018-10-30 13:21

    RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST NINE MONTHS 2018. REVENUES +5.1%, EBITDA +11.1%, OPERATING INCOME +9.6%, NET INCOME +8.2%. INTERIM DIVIDEND € 0.45 (+7.1%)

    2018, September 12

    THE NINTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI HAS ANNOUNCED THE CALL FOR NOMINATIONS

    2018-08-03 15:08

    Stock Options Granted

    2018, July 28

    Sole 24Ore: Notice Interim Report First Half 2018,

    2018-07-26 12:24

    RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES +6.9%, OPERATING INCOME +14.1%, NET INCOME +11.7%

    2018-07-04 21:38

    Shareholders Agreements

    2018, July 4

    SHAREHOLDERS AGREEMENTS,

    2018-07-02 18:01

    CVC AGREES TO ACQUIRE FIMEI S.P.A.

    2018-06-29 20:10

    CVC AGREES TO ACQUIRE FIMEI S.P.A.

    2018, June 29

    CVC Fund VII Acquires Controlling Stake in Recordati S.p.A.

    2018, June 11

    RECORDATI ACQUIRES NATURAL POINT S.R.L. IN ITALY

    2018-05-09 15:48

    Public Disclosure Compliance (shareholders' meeting minutes dated 18.04.18)

    2018-05-08 11:25

    RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST QUARTER 2018. REVENUES +7.2%, OPERATING INCOME +12.4%, NET INCOME +10.3%

    2018, April 19

    Sole24Ore - Notice of final dividend payment,

    2018, April 18

    Public Disclosure Compliance

    2018, April 9

    RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN

    2018-04-08 12:47

    RECORDATI: SHAREHOLDERS APPROVE THE 2017 ACCOUNTS. DIVIDEND € 0.85 PER SHARE (+21.4% vs 2016)

    2018-03-27 19:45

    Public disclosure compliance

    2018-03-19 17:23

    Pubblic Disclosure

    2018, March 16

    Sole24Ore - Call notice of the Ordinary Shareholders meeting - 18.04.2018,

    2018, March 16

    Sole24Ore - Notice of filing of 2017 Annual Report and Corporate Governance,

    2018-03-16 19:18

    Public Disclosure

    2018-03-15 12:14

    RECORDATI: BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%)

    2018-02-08 12:23

    RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +11.6%, OPERATING INCOME +24.1%, NET INCOME +21.6%

    2017, December 18

    RECORDATI ACQUIRES TRANSIPEG®, TRANSIPEGLIB® AND COLOPEG® FOR THE FRENCH MARKET,

    2017, November 29

    RECORDATI: 2018 CORPORATE EVENTS' CALENDAR,

    2017, October 27

    Notice: 2017 INTERIM DIVIDEND PAYMENT,

    2017-10-26 11:51

    RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%),

    2017, July 28

    Notice - Half Yearly Financial Report at 30 June 2017,

    2017-07-27 11:14

    RECORDATI: VERY GOOD RESULTS AGAIN IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%.,

    2017-07-19 18:13

    RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA,

    2017, July 7

    Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP),

    2017-07-03 08:01

    RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED,

    2017, June 16

    RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS,

    2017-05-22 08:01

    RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS IN EUROPE,

    2017, May 19

    European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia,

    2017-05-10 19:13

    Public disclosure compliance,

    2017-05-04 12:49

    RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%,

    2017-04-19 00:00

    Recordati establishes Canadian presence with launch of Recordati Rare Diseases Canada Inc.,

    2017-04-13 00:00

    Recordati Rare Diseases Inc. Acquires North American Marketing Rights to CYSTADANE®,

    2017, April 12

    Notice of 2016 final dividend payment,

    2017-04-11 14:11

    RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015),

    2017-04-07 18:35

    BoD resolution approving the merger registered with Companies Register

    2017-04-05 11:03

    BoD approves the merger of Recordati SA Chemical and Pharmaceutical Company in Recordati SPA

    2017-03-20 19:09

    RECORDATI: PUBLICATION OF LISTS OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR AND STATUTORY AUDITOR OF THE COMPANY

    2017-03-17 16:56

    Public disclosure

    2017-03-17 18:19

    RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS

    2017-03-19 17:47

    Public disclosure

    2017, March 2

    Notice of filing of 2016 Annual Report and merger notice to shareholders,

    2017-03-01 12:38

    RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%),

    2017-03-01 17:40

    Call notice of Ordinary and Extraordinary Shareholders Meeting 11 April 2017,

    2017-03-01 19:26

    Public disclosure

    2017-02-27 12:59

    RECORDATI: SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE,

    2017-02-09 12:23

    RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED,

    2017-02-01 08:35

    RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN,

    2017, January 27

    RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®,

    2016, December 14

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, December 14

    RECORDATI: 2017 CORPORATE EVENTS’ CALENDAR and DISCLOSURE OF QUARTERLY REPORTS,

    2016, December 6

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, December 1

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, November 24

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, November 17

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, November 15

    ERYTECH ANNOUNCES WITHDRAWAL OF ITS EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA FOR ACUTE LYMPHOBASTIC LEUKEMIA AND PREPARES FOR RESUBMISSION,

    2016, November 10

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, October 28

    Notice: 2016 INTERIM DIVIDEND PAYMENT,

    2016, October 27

    RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2016. CONTINUED GROWTH IN SALES +9.9%, OPERATING INCOME +18.5%, NET INCOME +19.5%,

    2016, October 2

    Recordati initiates a share buy-back program

    2016, August 16

    RECORDATI ANNOUNCES THAT ITS CHAIRMAN AND CEO GIOVANNI RECORDATI PASSED AWAY,

    2016, August 16

    RECORDATI: ALBERTO RECORDATI APPOINTED CHAIRMAN; ANDREA RECORDATI APPOINTED VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER,

    2016, August 2

    RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE,

    2016, July 29

    Notice - Half Yearly Financial Report at 30 June 2016,

    2016, July 28

    RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES +9.1%, OPERATING INCOME +17.2%, NET INCOME +18.9%,

    2016, July 14

    RECORDATI ACQUIRES THE SWISS PHARMACEUTICAL COMPANY PRO FARMA,

    2016, May 31

    RECORDATI ACQUIRES THE ITALIAN PHARMACEUTICAL COMPANY ITALCHIMICI,

    2016, May 5

    RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2016. SALES +9.6%, OPERATING INCOME +22.7%, NET INCOME +26.0%,

    2016, May 2

    Public Disclosure - Minutes SHM 13.4.2016

    2016, April 14

    Notice of 2015 final dividend payment,

    2016, April 13

    RECORDATI SHAREHOLDERS APPROVE THE 2015 ACCOUNTS. DIVIDEND € 0.60 PER SHARE (+20.0% vs 2014),

    2016, March 21

    PUBLIC DISCLOSURE

    2016, March 15

    PUBLIC DISCLOSURE

    2016, March 9

    Notice of filing of the 2015 Annual Report,

    2016, March 8

    SHGM Call notice 13 April 2016,

    2016, March 8

    RECORDATI: BOARD APPROVES THE 2015 ACCOUNTS. SALES € 1,047.7 MILLION (+6.1%), OPERATING INCOME € 278.5 MILLION (+20.6%) AND NET INCOME € 198.8 MILLION (+23.3%). 2015 DIVIDEND € 0.60 (+20.0%),

    2016, February 29

    RARE DISEASE DAY,

    2016, February 12

    Update on the execution of the share buy-back program

    2016, February 11

    RECORDATI PRELIMINARY 2015 RESULTS: REVENUE GROWTH AND FURTHER MARGIN IMPROVEMENT, SALES +6.1%, OPERATING INCOME +20.6% AND NET INCOME +23.3%

    2015, November 20

    2016 Corporate events' calendar,

    2015, October 29

    First nine months 2015 and 2015 interim dividend payment 2015,

    2015, October 28

    RECORDATI REPORTS SALES +5.7%, OPERATING INCOME +18.1% AND NET INCOME +23.0% IN THE FIRST NINE MONTHS 2015. THE INTERNATIONAL BUSINESS GROWS BY 8.8%,

    2015, October 15

    Update on the execution of the share buy-back program

    2015, October 6

    Update on the execution of the share buy-back program

    2015, September 14

    ERYTECH submits EMA Marketing Authorization,

    2015, September 8

    ORPHAN EUROPE Announces that Health Canada has Granted Market Authorization for Carbaglu® (carglumic acid),

    2015, July 30

    Notice of filing of yearly financial report 2015 of filing - half - yearly financial report 2015,

    2015, July 29

    RECORDATI REPORTS SALES +6.2%, OPERATING INCOME +19.2% AND NET INCOME +24.3% IN THE FIRST HALF 2015 THANKS TO ITS INTERNATIONAL BUSINESS,

    2015, June 13

    ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN J. V. MCMURRAY AND SALIM YUSUF,

    2015, May 15

    Update on the execution of the share buy-back program

    2015, May 6

    Notice of filing of First Quarter 2015,

    2015, May 5

    RECORDATI: SALES GROWTH AND FURTHER MARGIN IMPROVEMENT IN THE FIRST QUARTER 2015. SALES +5.9%, OPERATING INCOME +18.1%, NET INCOME +21.5%,

    2015, April 30

    Public disclosure compliance - Minutes of the Shareholders' meeting 15.4.2015

    2015, April 30

    Recordati initiates a share buy-back program

    2015, April 16

    Notice of 2014 final dividend payment,

    2015-04-15 18:07

    RECORDATI: RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013),

    2015, March 18

    Public Disclosure Compliance

    2015, March 5

    Avviso integrale di convocazione dell’Assemblea degli Azionisti del 15 aprile 2015,

    2015, March 5

    SHGM Call notice,

    2015, March 5

    Notice of filing of the 2014 Annual Report,

    2015, March 4

    RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET INCOME € 161.2 MILLION (+20.6%). 2014 DIVIDEND € 0.50 (+51.5%),

    2015-02-12 12:03

    RECORDATI: PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME +20.6%,

    2015, January 16

    RECORDATI: CHANGE TO 2015 CORPORATE EVENTS CALENDAR

    2014, November 28

    Recordati: 2015 Corporate Events’ Calendar,

    2014, October 28

    Notice of filing of First nine months 2014,

    2014, October 28

    Revenue growth and significant margin improvement in first nine months 2014 results. Sales +5.7%, operating income +21.6% and net income +22.2%,

    2014, October 9

    Recordati initiates a share buy-back program,

    2014, September 30

    ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia,

    2014, September 22

    Recordati: public disclosure compliance

    2014, September 16

    Recordati obtains license to new treatment for premature ejaculation from Plethora,

    2014, August 30

    The eighth edition of the Arrigo Recordati International Prize for Scientific Research issues the call for nominations,

    2014, August 1

    Recordati: public disclosure compliance

    2014, July 29

    Notice of filing of First Half 2014,

    2014, July 29

    Recordati reports excellent results in the first half 2014. Sales +6.3%, operating income +18.8% and net income +18.1,

    2014, July 3

    Recordati: Carbaglu® receives orphan drug designation in the U.S. For organic acidemias,

    2014, May 26

    Recordati finalizes the second tranche of its acquisition of Opalia Pharma in Tunisia,

    2014-04-17 14:11

    Recordati: Shareholders approve the 2013 accounts. Dividend € 0.33 per share.,

    2014, May 9

    Recordati: public disclosure compliance

    2014, May 6

    Notice of filing of First Quarter 2014,

    2014-05-06 07:33

    Recordati: sales growth and significant margin improvement in the first quarter 2014 (sales +6.5%, operating income +18.1%, net income +13.2%),

    2014, April 18

    Notice of 2013 final dividend payment,

    2014, April 11

    Recordati receives the special Award "Finance for Growth",

    2014, March 27

    Recordati: publication of lists of candidates for the appointment of Directors and Statutory Auditors of the company

    2014, March 24

    Recordati: notice pursuant to art. 144-octies, paragraph 2 of issuers' regulations

    2014, March 21

    Recordati: public disclosure compliance

    2014, March 14

    Recordati: public disclosure compliance

    2014, March 7

    Notice of filing of the 2013 Annual Report,

    2014, March 6

    Recordati: Board approves the2013 accounts. Revenue € 941.6 million (+13.7%), operating income € 195.4 million (+17.0%), net income € 133.7 million (+12.8%). 2013 dividend € 0.33 (+10.0%),

    2014, February 26

    The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare diseases on people's lives,

    2014, February 11

    Recordati: preliminary 2013 results show significant growth. Sales +13.7%, EBIT +17.0%, net income +12.8%. A productive year for investments,

    2014, February 10

    Recordati obtains Vitaros® license from Apricus Biosciences,

    2014, January 16

    Recordati Board of Directors approves 2014 objectives

    2013, December 17

    Recordati: 2014 corporate events' calendar,

    2013, October 31

    Interim Report - First nine months 2013 and 2013 interim dividend payment,

    2013, October 31

    Recordati finalizes the first tranche of its acquisition of Opalia Pharma in Tunisia,

    2013, October 30

    Recordati reports significant growth in the first nine months 2013. Sales +13.2%, operating income +12.0% and net income +9.0%. Interim dividend € 0.22 per share,

    2013, October 21

    Recordati finalizes its acquisition of Laboratorios Casen Fleet in Spain,

    2013, September 23

    Recordati: Andrea Recordati appointed Chief Operating Officer (COO),

    2013, September 17

    Recordati: update on the execution of the share buy-back program

    2013, September 9

    Recordati acquires the Spanish pharmaceutical company Laboratorios Casen Fleet,

    2013, September 6

    Recordati: update on the execution of the share buy-back program

    2013, July 26

    Notice of filing of First Half 2013,

    2013, July 25

    Recordati reports excellent results in the first half 2013. Sales +13.8%, operating income +13.8% and net income +11.1%,

    2013, July 24

    Recordati: update on the execution of the share buy-back program

    2013, July 24

    Recordati acquires the Tunisian pharmaceutical company Opalia Pharma,

    2013, July 3

    Recordati: update on the execution of the share buy-back program

    2013, June 24

    Recordati: update on the execution of the share buy-back program

    2013, June 15

    Arrigo Recordati International Prize for Scientific Research awarded to Filippo Crea,

    2013, June 14

    Recordati: update on the execution of the share buy-back program

    2013, June 6

    Recordati: update on the execution of the share buy-back program

    2013, May 29

    Recordati: update on the execution of the share buy-back program

    2013, May 21

    Recordati: update on the execution of the share buy-back program

    2013, May 10

    Notice of filing of First Quarter 2013,

    2013-05-09 12:01

    Recordati: initiates a share buy-back program,

    2013, May 9

    Recordati: significant sales and earnings growth in the first quarter 2013 (sales +11.4%, net income +11.8%) thanks to the international business (+16.1%),

    2013, May 7

    Recordati: Public disclosure compliance - Minutes SHGM 17.4.2013

    2013, April 18

    Notice of 2012 final dividend payment,

    2013, April 17

    Recordati: shareholders approve the 2012 accounts. Dividend € 0.30 per share,

    2013, March 22

    Recordati: public disclosure compliance - Publication Remuneration report

    2013, March 15

    Recordat: public disclosure compliance – Publications of the Directors’ reports

    2013, March 15

    Shareholders' Meeting Call Notice,

    2013, March 15

    Shareholders' Meeting Call Notice,

    2013, March 14

    Recordati: Board approves a supplement to the agenda of the annual meeting of shareholders

    2013, March 14

    Recordati: public disclosure compliance

    2013, March 8

    Notice of filing of the 2012 Annual Report,

    2013, March 7

    Recordati: Board approves the 2012 accounts. Revenue € 828.3 million (+8.7%), operating income € 167.0 million (+2.1%), net income € 118.5 million (+1.8%). 2012 dividend € 0.30,

    2013, February 12

    Recordati: positive preliminary 2012 results. Sales +8.7%, EBIT +2.1%, net income +1.8%. A productive year for investments,

    2013-02-04 08:35

    Recordati to meet with the financial community and specialized press in Milan,

    2013, January 31

    Recordati: update on the execution of the share buy-back program

    2013, January 21

    Recordati finalizes its acquisition of a portfolio of products in the USA

    2012, May 8

    Recordati: good first quarter 2012 results (revenue +11.0%, net income +7.5%) thanks to the growth of the international business (+14.5%),

  • Announcements
    2024, May 16

    THE WINNER OF THE 11TH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI ANNOUNCED

    2024-05-13 13:14

    RECORDATI: PUBLICATION OF DOCUMENTS

    2024-05-09 17:04

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS

    2024-05-09 13:03

    THE STRONG PERFORMANCE OF THE GROUP CONTINUES IN THE FIRST QUARTER OF 2024: REVENUE +10.2%, EBITDA +10.5%, ADJUSTED NET INCOME +5.6%

    2024-04-24 19:18

    RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 22.04.2024

    2024, April 23

    Press release (on "il Sole 24 Ore") - 2023 final payment dividend

    2024-04-22 13:22

    RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2023 FINANCIAL STATEMENTS AND THE DIVIDEND OF € 1.20 PER SHARE (+4.3% vs 2022)

    2024-04-11 19:15

    RECORDATI: CONCLUSION OF THE SHARE BUY-BACK PROGRAM INITIATED ON 2nd OCTOBER 2023.

    2024, March 29

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance Report 2023

    2024-03-28 17:32

    RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024

    2024-03-22 19:43

    RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024

    2024, March 20

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 22.04.2024

    2024-03-19 12:25

    RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)

    2024-02-22 12:45

    FY 2023 PRELIMINARY RESULTS AT TOP END OF GUIDANCE: REVENUE +12.4%, EBITDA +14.4%, ADJUSTED NET INCOME +10.8%. FY 2024 TARGETS REFLECT CONTINUED GROWTH ACROSS ALL KEY METRICS

    2024-01-29 18:04

    RECORDATI: 2024 CORPORATE EVENTS’ CALENDAR

    2023, November 8

    Press release (on "il Sole 24 Ore") - 2023 Interim Dividend Payment

    2023-11-07 12:33

    FIRST NINE MONTHS 2023 AHEAD OF PLAN: REVENUE +13.0%, EBITDA +15.4%, ADJUSTED NET INCOME +14.2%. 2025 REVENUE AND PROFITS EXPECTED TO EXCEED TARGETS SET IN FEBRUARY 2023

    2023, October 16

    RECORDATI APPOINTS MILAN ZDRAVKOVIC AS EXECUTIVE VICE PRESIDENT R&D

    2023-09-29 18:03

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS

    2023, August 1

    Press release (on il Sole 24 Ore) - Interim Report First Half 2023

    2023, July 31

    RECORDATI: PUBLIC DISCLOSURE - INTERIM FINANCIAL STATEMENTS

    2023-07-28 12:43

    FIRST HALF 2023 RESULTS CONFIRM STRONG MOMENTUM OF THE GROUP: REVENUE +17.0%, EBITDA +21.3%, ADJUSTED NET INCOME +27.9%. RECENT TRANSACTION WITH GSK FURTHER STRENGTHENS SPC UROLOGY FRANCHISE

    2023-07-20 17:48

    RECORDATI: AGREEMENT FOR THE DISTRIBUTION OF AVODART® AND COMBODART® IN EUROPE

    2023-06-27 18:11

    RECORDATI: PERFORMANCE SHARE PLAN 2023-2025 ASSIGNMENT OF RIGHTS PROVIDED UNDER THE FIRST CYCLE

    2023, May 19

    LAUNCH OF THE 11TH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH

    2023-05-17 11:53

    RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023-05-11 13:48

    FIRST QUARTER 2023 RESULTS: REVENUE +31.5%, EBITDA(1) +35.4%, ADJUSTED NET INCOME(2) +33.3%. FY 2023 GUIDANCE REVISED UPWARDS

    2023, April 22

    Press release (on "il Sole 24 Ore") - 2022 final payment dividend

    2023, April 21

    RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023-04-21 17:12

    RECORDATI: SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023, March 31

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2022,

    2023-03-21 16:14

    RECORDATI: PUBLICATION OF THE SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY PUBLICATION OF SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS

    2023-03-30 13:37

    RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

    2023-03-27 19:09

    RECORDATI: FILING OF A SOLE SLATE FOR THE RENEWAL OF THE BOARD OF STATUTORY AUDITORS – EXTENSION OF THE DEADLINE AND REDUCTION BY HALF OF THE PARTICIPATION REQUIREMENTS FOR THE FILING

    2023-03-22 18:23

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023)

    2023-03-16 12:34

    RECORDATI BOARD APPROVES THE 2022 ACCOUNTS, CONFIRMING STRONG CONSOLIDATED FINANCIAL RESULTS: REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2022 DIVIDEND € 1.15 (+4.5%),

    2023, March 11

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 21.04.2023,

    2023-03-10 12:53

    RECORDATI: ORDINARY GENERAL MEETING OF SHAREHOLDERS CONVENED FOR 21 APRIL 2023, IN A SINGLE CALL. DOCUMENTS RELATING TO THE GENERAL MEETING.,

    2023-02-21 12:59

    RECORDATI: STRONG PRELIMINARY 2022 FINANCIAL RESULTS. REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2023-2025 THREE-YEAR PLAN APPROVED; 2025 REVENUE TARGET BETWEEN € 2,250 AND € 2,350 MILLION,

    2023-01-16 18:09

    RECORDATI: 2023 CORPORATE EVENTS’ CALENDAR,

    2022, November 9

    Press release (on "il Sole 24 Ore") - 2022 Interim Dividend Payment,

    2022-11-08 13:01

    RECORDATI: RESULTS OF FIRST NINE MONTHS OF 2022 AHEAD OF EXPECTATIONS. REVENUE +19.1%, EBITDA(1) +15.2% AND ADJUSTED NET INCOME(2) +13.5%. FY 2022 RESULTS GUIDANCE REVISED UPWARDS,

    2022, August 2

    Press release (on il Sole 24 Ore) - Interim Report First Half 2022,

    2022-08-02 18:06

    RECORDATI: PUBLIC DISCLOSURE

    2022-08-01 14:31

    RECORDATI: PUBLIC DISCLOSURE

    2022-07-28 13:28

    RECORDATI FIRST HALF 2022 RESULTS: REVENUE +15.8%, EBITDA +11.5%, ADJUSTED NET INCOME +7.1%.,

    2022-06-20 07:33

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2022, May 23

    THE TENTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI COMES TO END,

    2022-05-13 17:09

    RECORDATI: MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022

    2022-05-10 11:56

    RECORDATI: FIRST QUARTER 2022 RESULTS APPROVED, REVENUE +9.0%, EBITDA +8.7%. 2022 TARGETS CONFIRMED,

    2022-05-03 12:45

    RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022

    2022, April 30

    Press release (on "il Sole 24 Ore") - 2021 final payment dividend,

    2022-04-29 12:44

    RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2021 FINANCIAL STATEMENTS. DIVIDEND OF € 1.10 PER SHARE (+4.8% vs 2020). THE NEW BOARD OF DIRECTORS HAS BEEN APPOINTED,

    2022-04-08 16:52

    RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.,

    2022-04-08 16:52

    RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE SLATE AND OF THE RESOLUTION PROPOSALS FOR THE SHAREHOLDERS’ MEETING OF 29 APRIL 2022.

    2022, April 2

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2021,

    2022-04-01 17:34

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)

    2022, March 19

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2022,

    2022-03-18 16:18

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)

    2022-03-17 17:44

    RECORDATI: BOARD APPROVES THE 2021 ACCOUNTS. SALES € 1,580.1 MILLION (+9.1%), EBITDA(1) € 602.3 MILLION (+5.8%) ADJUSTED NET INCOME € 386.0 MILLION (+8.7%). 2021 DIVIDEND € 1.10 (+4.8%),

    2022-03-16 18:03

    RECORDATI COMPLETES THE ACQUISITION OF EUSA PHARMA (UK),

    2022-02-24 13:18

    RECORDATI: PRELIMINARY 2021 RESULTS IN LINE WITH TARGETS REVENUE +9.1%, EBITDA +5.8%, NET INCOME +8.7%,

    2021-12-16 13:52

    RECORDATI: KIM STRATTON CO-OPTED TO THE BOARD OF DIRECTORS AS A NON-EXECUTIVE AND NON-INDEPENDENT DIRECTOR,

    2021-12-03 07:32

    RECORDATI TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND NICHE ONCOLOGY DISEASES,

    2021-12-01 10:09

    RECORDATI: ANDREA RECORDATI APPOINTED CHAIRMAN AND ROBERT KOREMANS APPOINTED CHIEF EXECUTIVE OFFICER,

    2021-10-29 18:27

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS RECORDATI SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2021, October 29

    Press release (on "il Sole 24 Ore") - 2021 Interim Dividend Payment,

    2021-10-28 13:22

    RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES,

    2021-10-11 19:11

    RECORDATI: RESIGNATION OF A NON-EXECUTIVE DIRECTOR,

    2021-10-11 12:24

    RECORDATI: 2022 CORPORATE EVENTS’ CALENDAR,

    2021, July 30

    Press release (on "il Sole 24 Ore") - Interim Report First Half 2021,

    2022-07-30 15:50

    RECORDATI: PUBLIC DISCLOSURE

    2021-07-29 12:04

    RECORDATI: FIRST HALF OF 2021 RESULTS APPROVED, REVENUE +1.4%, EBITDA -3.4%, NET INCOME +5.2%. RETURN TO GROWTH IN THE SECOND QUARTER,

    2021-07-16 07:31

    RECORDATI: Rob Koremans new Chief Executive Officer effective 1 December 2021, Andrea Recordati to be appointed as Chairman.,

    2021, July 14

    RECORDATI SUPPORTS THE FORESTAMI PROJECT,

    2021-07-09 07:50

    STRENGTHENING OF THE CORPORATE GOVERNANCE,

    2021-05-05 17:17

    RECORDATI: PUBLIC DISCLOSURE (MINUTES OF THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021, May 25

    THE TENTH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH HAS ANNOUNCED THE CALL FOR APPLICATIONS,

    2021-05-06 13:12

    RECORDATI: FIRST QUARTER 2021 RESULTS AND 2021-2023 THREE-YEAR PLAN APPROVED; 2023 REVENUE FORECAST BETWEEN €1,900 AND € 2,000 MILLION,

    2021-04-28 09:37

    RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE,

    2021-03-23 00:00

    RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE,

    2021-04-22 12:22

    RECORDATI: REGISTRATION WITH THE COMPANIES’ REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED,

    2021-04-22 11:25

    RECORDATI: PUBLIC DISCLOSURE (SUMMARY REPORT OF THE VOTES - ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021, April 21

    Press release (on "il Sole 24 Ore") - 2020 final payment dividend,

    2021-04-20 12:47

    RECORDATI: SHAREHOLDERS APPROVE THE 2020 ACCOUNTS. DIVIDEND € 1.05 PER SHARE (+5.0% vs 2019).,

    2021-04-12 18:13

    RECORDATI: THE MERGER DEED RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. HAS BEEN EXECUTED,

    2021, March 30

    Press release (on "il Sole 24 Ore") - Annual Financial Report, Non-Financial Statement and Corporate Governance 2020,

    2021-03-29 18:12

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021, March 25

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 20.04.2021)

    2021, March 24

    RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN JAPAN,

    2021, March 20

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 20.04.2021,

    2021-03-19 18:59

    RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

    2021-03-18 16:42

    RECORDATI: BOARD APPROVES THE 2020 ACCOUNTS. SALES € 1,448.9 MILLION (-2.2%), EBITDA € 569.3 MILLION (+4.7%) ADJUSTED NET INCOME € 410.4 MILLION (+7.3%). 2020 DIVIDEND € 1.05 (+ 5.0 %),

    2021-02-22 18:25

    RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2021-02-22 12:58

    RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING AND NET INCOME. EBITDA +4.7% AND ADJ NET INCOME +7.3%,

    2021-01-29 18:06

    RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES,

    2021, January 26

    RECORDATI: CARBAGLU receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia

    2020-12-29 11:10

    Public disclosure

    2020-12-18 12:41

    Public disclosure

    2020-12-17 18:04

    RECORDATI: MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. APPROVED BY THE EXTRAORDINARY SHAREHOLDERS’ MEETING,

    2020-12-09 18:04

    RECORDATI: TAX PETITION FOR THE FRUITION OF ACE TAX BENEFITS DERIVING FROM THE REVERSE MERGER OBTAINED POSITIVE ANSWER,

    2020-11-30 18:04

    RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY,

    2021-11-30 00:00

    RECORDATI: 2021 CORPORATE EVENTS’ CALENDAR,

    2020, November 14

    Press release - (on "Milano Finanza") - Extract of the call notice of the extraordinary general meeting of the shareholders 17.12.2020,

    2020-11-13 17:42

    Call to an extraordinary general meeting of the shareholders 17.12.2020 (Reverse Merger),

    2021-03-25 15:04

    RECORDATI: PUBLICATION OF DOCUMENTATION RELATED TO THE REVERSE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.

    2020, October 30

    Press release (on "il Sole 24 Ore") - 2020 Interim Dividend Payment,

    2020-10-29 13:11

    RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%,

    2020-10-07 15:15

    RECORDATI: PUBLICATION OF THE INFORMATION DOCUMENT RELATING TO MAJOR TRANSACTIONS WITH RELATED PARTIES

    2021-05-25 15:04

    RECORDATI: FILING OF THE MERGER PLAN RELATING TO THE MERGER BY ABSORPTION OF ROSSINI INVESTIMENTI S.p.A. AND FIMEI S.p.A. INTO RECORDATI S.p.A.

    2020-10-01 18:07

    RECORDATI: RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED,

    2020-09-21 00:00

    RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION,

    2020-08-25 00:00

    RECORDATI: U.S. FDA APPROVES CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A NEW PRACTICAL TREATMENT OPTION FOR THE OCULAR MANIFESTATIONS OF CYSTINOSIS,

    2020-08-03 17:06

    Public disclosure compliance

    2020, July 31

    Press release (on "il Sole 24 Ore") - Interim Report First Half 2020,

    2020-07-30 13:53

    RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%,

    2020-07-17 13:53

    ISTURISA® IS NOW AVAILABLE AS A MEDICAL TREATMENT FOR CUSHING'S SYNDROME IN GERMANY,

    2020-06-17 13:52

    RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE,

    2020, June 2

    Recordati Rare Diseases announces first European launch of Isturisa® (osilodrostat),

    2020-05-27 12:30

    Public disclosure

    2020, May 27

    RECORDATI RARE DISEASES INC. ANNOUNCES AVALABILITY OF ISTURISA® (OSILODROSTAT) IN THE UNITED STATES,

    2020-05-07 12:35

    RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%,

    2020, April 30

    Press release (on "il Sole 24 Ore") - 2019 final payment dividend,

    2020-04-03 17:50

    Public disclosure

    2020-04-29 12:11

    RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018),

    2020-04-17 18:15

    RECORDATI: PROPOSAL OF CANDIDATES FOR THE OFFICE OF DIRECTORS AND THEIR RELATIVE REMUNERATION PRESENTED BY THE MAJORITY SHAREHOLDER FIMEI SpA IN RELATION TO ITEM 2 ON THE SHAREHOLDERS’ MEETING AGENDA

    2020-04-08 10:46

    Public disclosure

    2020-04-08 18:54

    RECORDATI: PUBLICATION OF THE LIST OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY

    2020, April 8

    Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome,

    2020-04-04 18:28

    RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS

    2020-03-30 12:24

    Public disclosure

    2020, March 26

    RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN,

    2020, March 25

    Press release (on "il Sole 24 Ore") - 2019 financial statements and corporate governance report,

    2020-03-24 17:36

    Public Disclosure

    2020, March 20

    Press release (on "il Sole 24 Ore") - Extract of the call notice of the Ordinary Shareholders meeting 29.04.2020,

    2020-03-19 17:56

    Public disclosure

    2020-03-18 14:11

    BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).,

    2020, March 18

    RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19,

    2020-03-12 19:59

    RECORDATI: LAUNCH OF A NEW SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2020-03-09 08:32

    RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN THE U.S.,

    2020-02-17 19:29

    RECORDATI: LAUNCH OF A SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS,

    2020-02-14 14:04

    RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%.,

    2020, February 4

    RECORDATI: CHANGE IN 2020 CORPORATE EVENTS’ CALENDAR,

    2020-01-15 12:01

    RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED,

    2019-11-15 17:24

    RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT),

    2019, November 12

    RECORDATI: 2020 CORPORATE EVENTS' CALENDAR,

    2019, November 1

    Press release - 2019 Interim dividend payment,

    2019-10-31 12:58

    RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%).,

    2019, October 29

    INAUGURAZIONE DEL PADIGLIONE GIOVANNI RECORDATI ALL'OSPEDALE DEI BAMBINI VITTORE BUZZI,

    2019-10-23 12:03

    RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED,

    2019, September 5

    ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO ALBERTO AURICCHIO,

    2019-07-31 19:15

    Public disclosure compliance

    2019, July 31

    Sole24Ore - Notice Interim Report First Half 2019,

    2019-07-30 13:10

    RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA +7.4%, NET INCOME +6.1%,

    2019-07-12 20:15

    RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699),

    2019, June 24

    RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS,

    2019-05-08 12:24

    RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED,

    2019-05-03 16:47

    Public Disclosure Compliance

    2019-04-15 19:07

    Public Disclosure Compliance

    2019-04-15 09:06

    RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY,

    2019, April 12

    Press Release - Notice on 2018 final payment dividend,

    2019-04-11 14:38

    RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017),

    2019-03-20 18:57

    Public Disclosure

    2019-03-12 18:23

    Public Disclosure

    2019-03-08 10:45

    Public Disclosure

    2019, March 5

    Press release - Notice of filing of 2018 Annual Report and Corporate Governance,

    2019-03-05 19:23

    Public Disclosure

    2019, March 5

    Sole24Ore - Extract of the call notice of the Ordinary Shareholders meeting - 11.04.2019,

    2019-03-04 18:18

    Public Disclosure

    2019-02-28 15:08

    RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%),

    2019-02-11 12:54

    RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%.,

    2019, February 6

    Public Disclosure Compliance

    2019, February 6

    RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN,

    2019, February 5

    RECORDATI: SHAREHOLDERS APPOINT THE NEW BOARD OF DIRECTORS. THE BOARD OF DIRECTORS APPOINTS FLEMMING ØRNSKOV AS CHAIRMAN AND CONFIRMS ANDREA RECORDATI AS CHIEF EXECUTIVE OFFICER,

    2019, February 1

    RECORDATI: TERMINATION BY MUTUAL AGREEMENT OF THE EMPLOYMENT RELATIONSHIP WITH ALBERTO RECORDATI

    2019, January 28

    RECORDATI: 2019 CORPORATE EVENTS' CALENDAR,

    2019-01-11 17:30

    RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY A GROUP OF ASSET MANAGEMENT COMPANIES AND INSTITUTIONAL INVESTORS

    2019-01-07 14:54

    RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY FIMEI S.P.A

    2019, January 7

    Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate

    2019, January 7

    Press release on behalf of FIMEI S.p.A. - New Recordati Board members proposed by majority shareholder FIMEI, including Dr. Flemming Ørnskov as Chairman designate

    2018, December 31

    RECORDATI CLOSES ACQUISITION OF TONIPHARM S.A.S. IN FRANCE

    2018-12-21 16:38

    RECORDATI: EXPECTATIONS FOR 2018 CONFIRMED AND 2019 OBJECTIVES ANNOUNCED; APPROVAL OF THE ISSUER’S NOTICE PURSUANT TO ART. 103 PARA. 3 OF ITALIAN LEGISLATIVE DECREE 58/1998, WITH REFERENCE TO THE PUBLIC MANDATORY TENDER OFFER FOR THE TOTAL NUMBER OF ORDINARY SHARES OF RECORDATI S.P.A.

    2018, December 21

    RECORDATI ACQUIRES TONIPHARM S.A.S. IN FRANCE

    2018, December 20

    Sole24Ore: Call notice of the Ordinary Shareholders Meeting 5 February 2019,

    2018, December 20

    RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®

    2018-12-19 19:41

    Public Disclosure

    2018-12-12 20:13

    Shareholders Agreements

    2018-12-11 19:18

    Publication of the abstract of the Shareholders' Agreements

    2018-12-06 18:01

    RECORDATI: RESIGNATION OF BOARD MEMBERS; CO-OPTION OF THREE NEW DIRECTORS; APPOINTMENT OF CHAIRMAN; AN ORDINARY GENERAL MEETING OF THE SHAREHOLDERS IS CONVENED TO APPOINT A NEW BOARD OF DIRECTORS

    2018, December 5

    RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR NEUROTROPHIC KERATITIS

    2018, November 5

    RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR MSUD

    2018, October 31

    Notice: 2018 interim dividend payment,

    2018-10-30 13:21

    RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST NINE MONTHS 2018. REVENUES +5.1%, EBITDA +11.1%, OPERATING INCOME +9.6%, NET INCOME +8.2%. INTERIM DIVIDEND € 0.45 (+7.1%)

    2018, September 12

    THE NINTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI HAS ANNOUNCED THE CALL FOR NOMINATIONS

    2018-08-03 15:08

    Stock Options Granted

    2018, July 28

    Sole 24Ore: Notice Interim Report First Half 2018,

    2018-07-26 12:24

    RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES +6.9%, OPERATING INCOME +14.1%, NET INCOME +11.7%

    2018-07-04 21:38

    Shareholders Agreements

    2018, July 4

    SHAREHOLDERS AGREEMENTS,

    2018-07-02 18:01

    CVC AGREES TO ACQUIRE FIMEI S.P.A.

    2018-06-29 20:10

    CVC AGREES TO ACQUIRE FIMEI S.P.A.

    2018, June 29

    CVC Fund VII Acquires Controlling Stake in Recordati S.p.A.

    2018, June 11

    RECORDATI ACQUIRES NATURAL POINT S.R.L. IN ITALY

    2018-05-09 15:48

    Public Disclosure Compliance (shareholders' meeting minutes dated 18.04.18)

    2018-05-08 11:25

    RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST QUARTER 2018. REVENUES +7.2%, OPERATING INCOME +12.4%, NET INCOME +10.3%

    2018, April 19

    Sole24Ore - Notice of final dividend payment,

    2018, April 18

    Public Disclosure Compliance

    2018, April 9

    RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN

    2018-04-08 12:47

    RECORDATI: SHAREHOLDERS APPROVE THE 2017 ACCOUNTS. DIVIDEND € 0.85 PER SHARE (+21.4% vs 2016)

    2018-03-27 19:45

    Public disclosure compliance

    2018-03-19 17:23

    Pubblic Disclosure

    2018, March 16

    Sole24Ore - Call notice of the Ordinary Shareholders meeting - 18.04.2018,

    2018, March 16

    Sole24Ore - Notice of filing of 2017 Annual Report and Corporate Governance,

    2018-03-16 19:18

    Public Disclosure

    2018-03-15 12:14

    RECORDATI: BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%)

    2018-02-08 12:23

    RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +11.6%, OPERATING INCOME +24.1%, NET INCOME +21.6%

    2017, December 18

    RECORDATI ACQUIRES TRANSIPEG®, TRANSIPEGLIB® AND COLOPEG® FOR THE FRENCH MARKET,

    2017, November 29

    RECORDATI: 2018 CORPORATE EVENTS' CALENDAR,

    2017, October 27

    Notice: 2017 INTERIM DIVIDEND PAYMENT,

    2017-10-26 11:51

    RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%),

    2017, July 28

    Notice - Half Yearly Financial Report at 30 June 2017,

    2017-07-27 11:14

    RECORDATI: VERY GOOD RESULTS AGAIN IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%.,

    2017-07-19 18:13

    RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA,

    2017, July 7

    Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP),

    2017-07-03 08:01

    RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED,

    2017, June 16

    RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS,

    2017-05-22 08:01

    RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS IN EUROPE,

    2017, May 19

    European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia,

    2017-05-10 19:13

    Public disclosure compliance,

    2017-05-04 12:49

    RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%,

    2017-04-19 00:00

    Recordati establishes Canadian presence with launch of Recordati Rare Diseases Canada Inc.,

    2017-04-13 00:00

    Recordati Rare Diseases Inc. Acquires North American Marketing Rights to CYSTADANE®,

    2017, April 12

    Notice of 2016 final dividend payment,

    2017-04-11 14:11

    RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015),

    2017-04-07 18:35

    BoD resolution approving the merger registered with Companies Register

    2017-04-05 11:03

    BoD approves the merger of Recordati SA Chemical and Pharmaceutical Company in Recordati SPA

    2017-03-20 19:09

    RECORDATI: PUBLICATION OF LISTS OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR AND STATUTORY AUDITOR OF THE COMPANY

    2017-03-17 16:56

    Public disclosure

    2017-03-17 18:19

    RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS’ REGULATIONS

    2017-03-19 17:47

    Public disclosure

    2017, March 2

    Notice of filing of 2016 Annual Report and merger notice to shareholders,

    2017-03-01 12:38

    RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%),

    2017-03-01 17:40

    Call notice of Ordinary and Extraordinary Shareholders Meeting 11 April 2017,

    2017-03-01 19:26

    Public disclosure

    2017-02-27 12:59

    RECORDATI: SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE,

    2017-02-09 12:23

    RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED,

    2017-02-01 08:35

    RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN,

    2017, January 27

    RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®,

    2016, December 14

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, December 14

    RECORDATI: 2017 CORPORATE EVENTS’ CALENDAR and DISCLOSURE OF QUARTERLY REPORTS,

    2016, December 6

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, December 1

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, November 24

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, November 17

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, November 15

    ERYTECH ANNOUNCES WITHDRAWAL OF ITS EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA FOR ACUTE LYMPHOBASTIC LEUKEMIA AND PREPARES FOR RESUBMISSION,

    2016, November 10

    UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

    2016, October 28

    Notice: 2016 INTERIM DIVIDEND PAYMENT,

    2016, October 27

    RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2016. CONTINUED GROWTH IN SALES +9.9%, OPERATING INCOME +18.5%, NET INCOME +19.5%,

    2016, October 2

    Recordati initiates a share buy-back program

    2016, August 16

    RECORDATI ANNOUNCES THAT ITS CHAIRMAN AND CEO GIOVANNI RECORDATI PASSED AWAY,

    2016, August 16

    RECORDATI: ALBERTO RECORDATI APPOINTED CHAIRMAN; ANDREA RECORDATI APPOINTED VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER,

    2016, August 2

    RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE,

    2016, July 29

    Notice - Half Yearly Financial Report at 30 June 2016,

    2016, July 28

    RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES +9.1%, OPERATING INCOME +17.2%, NET INCOME +18.9%,

    2016, July 14

    RECORDATI ACQUIRES THE SWISS PHARMACEUTICAL COMPANY PRO FARMA,

    2016, May 31

    RECORDATI ACQUIRES THE ITALIAN PHARMACEUTICAL COMPANY ITALCHIMICI,

    2016, May 5

    RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2016. SALES +9.6%, OPERATING INCOME +22.7%, NET INCOME +26.0%,

    2016, May 2

    Public Disclosure - Minutes SHM 13.4.2016

    2016, April 14

    Notice of 2015 final dividend payment,

    2016, April 13

    RECORDATI SHAREHOLDERS APPROVE THE 2015 ACCOUNTS. DIVIDEND € 0.60 PER SHARE (+20.0% vs 2014),

    2016, March 21

    PUBLIC DISCLOSURE

    2016, March 15

    PUBLIC DISCLOSURE

    2016, March 9

    Notice of filing of the 2015 Annual Report,

    2016, March 8

    SHGM Call notice 13 April 2016,

    2016, March 8

    RECORDATI: BOARD APPROVES THE 2015 ACCOUNTS. SALES € 1,047.7 MILLION (+6.1%), OPERATING INCOME € 278.5 MILLION (+20.6%) AND NET INCOME € 198.8 MILLION (+23.3%). 2015 DIVIDEND € 0.60 (+20.0%),

    2016, February 29

    RARE DISEASE DAY,

    2016, February 12

    Update on the execution of the share buy-back program

    2016, February 11

    RECORDATI PRELIMINARY 2015 RESULTS: REVENUE GROWTH AND FURTHER MARGIN IMPROVEMENT, SALES +6.1%, OPERATING INCOME +20.6% AND NET INCOME +23.3%

    2015, November 20

    2016 Corporate events' calendar,

    2015, October 29

    First nine months 2015 and 2015 interim dividend payment 2015,

    2015, October 28

    RECORDATI REPORTS SALES +5.7%, OPERATING INCOME +18.1% AND NET INCOME +23.0% IN THE FIRST NINE MONTHS 2015. THE INTERNATIONAL BUSINESS GROWS BY 8.8%,

    2015, October 15

    Update on the execution of the share buy-back program

    2015, October 6

    Update on the execution of the share buy-back program

    2015, September 14

    ERYTECH submits EMA Marketing Authorization,

    2015, September 8

    ORPHAN EUROPE Announces that Health Canada has Granted Market Authorization for Carbaglu® (carglumic acid),

    2015, July 30

    Notice of filing of yearly financial report 2015 of filing - half - yearly financial report 2015,

    2015, July 29

    RECORDATI REPORTS SALES +6.2%, OPERATING INCOME +19.2% AND NET INCOME +24.3% IN THE FIRST HALF 2015 THANKS TO ITS INTERNATIONAL BUSINESS,

    2015, June 13

    ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN J. V. MCMURRAY AND SALIM YUSUF,

    2015, May 15

    Update on the execution of the share buy-back program

    2015, May 6

    Notice of filing of First Quarter 2015,

    2015, May 5

    RECORDATI: SALES GROWTH AND FURTHER MARGIN IMPROVEMENT IN THE FIRST QUARTER 2015. SALES +5.9%, OPERATING INCOME +18.1%, NET INCOME +21.5%,

    2015, April 30

    Public disclosure compliance - Minutes of the Shareholders' meeting 15.4.2015

    2015, April 30

    Recordati initiates a share buy-back program

    2015, April 16

    Notice of 2014 final dividend payment,

    2015-04-15 18:07

    RECORDATI: RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013),

    2015, March 18

    Public Disclosure Compliance

    2015, March 5

    Avviso integrale di convocazione dell’Assemblea degli Azionisti del 15 aprile 2015,

    2015, March 5

    SHGM Call notice,

    2015, March 5

    Notice of filing of the 2014 Annual Report,

    2015, March 4

    RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET INCOME € 161.2 MILLION (+20.6%). 2014 DIVIDEND € 0.50 (+51.5%),

    2015-02-12 12:03

    RECORDATI: PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME +20.6%,

    2015, January 16

    RECORDATI: CHANGE TO 2015 CORPORATE EVENTS CALENDAR

    2014, November 28

    Recordati: 2015 Corporate Events’ Calendar,

    2014, October 28

    Notice of filing of First nine months 2014,

    2014, October 28

    Revenue growth and significant margin improvement in first nine months 2014 results. Sales +5.7%, operating income +21.6% and net income +22.2%,

    2014, October 9

    Recordati initiates a share buy-back program,

    2014, September 30

    ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia,

    2014, September 22

    Recordati: public disclosure compliance

    2014, September 16

    Recordati obtains license to new treatment for premature ejaculation from Plethora,

    2014, August 30

    The eighth edition of the Arrigo Recordati International Prize for Scientific Research issues the call for nominations,

    2014, August 1

    Recordati: public disclosure compliance

    2014, July 29

    Notice of filing of First Half 2014,

    2014, July 29

    Recordati reports excellent results in the first half 2014. Sales +6.3%, operating income +18.8% and net income +18.1,

    2014, July 3

    Recordati: Carbaglu® receives orphan drug designation in the U.S. For organic acidemias,

    2014, May 26

    Recordati finalizes the second tranche of its acquisition of Opalia Pharma in Tunisia,

    2014-04-17 14:11

    Recordati: Shareholders approve the 2013 accounts. Dividend € 0.33 per share.,

    2014, May 9

    Recordati: public disclosure compliance

    2014, May 6

    Notice of filing of First Quarter 2014,

    2014-05-06 07:33

    Recordati: sales growth and significant margin improvement in the first quarter 2014 (sales +6.5%, operating income +18.1%, net income +13.2%),

    2014, April 18

    Notice of 2013 final dividend payment,

    2014, April 11

    Recordati receives the special Award "Finance for Growth",

    2014, March 27

    Recordati: publication of lists of candidates for the appointment of Directors and Statutory Auditors of the company

    2014, March 24

    Recordati: notice pursuant to art. 144-octies, paragraph 2 of issuers' regulations

    2014, March 21

    Recordati: public disclosure compliance

    2014, March 14

    Recordati: public disclosure compliance

    2014, March 7

    Notice of filing of the 2013 Annual Report,

    2014, March 6

    Recordati: Board approves the2013 accounts. Revenue € 941.6 million (+13.7%), operating income € 195.4 million (+17.0%), net income € 133.7 million (+12.8%). 2013 dividend € 0.33 (+10.0%),

    2014, February 26

    The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare diseases on people's lives,

    2014, February 11

    Recordati: preliminary 2013 results show significant growth. Sales +13.7%, EBIT +17.0%, net income +12.8%. A productive year for investments,

    2014, February 10

    Recordati obtains Vitaros® license from Apricus Biosciences,

    2014, January 16

    Recordati Board of Directors approves 2014 objectives

    2013, December 17

    Recordati: 2014 corporate events' calendar,

    2013, October 31

    Interim Report - First nine months 2013 and 2013 interim dividend payment,

    2013, October 31

    Recordati finalizes the first tranche of its acquisition of Opalia Pharma in Tunisia,

    2013, October 30

    Recordati reports significant growth in the first nine months 2013. Sales +13.2%, operating income +12.0% and net income +9.0%. Interim dividend € 0.22 per share,

    2013, October 21

    Recordati finalizes its acquisition of Laboratorios Casen Fleet in Spain,

    2013, September 23

    Recordati: Andrea Recordati appointed Chief Operating Officer (COO),

    2013, September 17

    Recordati: update on the execution of the share buy-back program

    2013, September 9

    Recordati acquires the Spanish pharmaceutical company Laboratorios Casen Fleet,

    2013, September 6

    Recordati: update on the execution of the share buy-back program

    2013, July 26

    Notice of filing of First Half 2013,

    2013, July 25

    Recordati reports excellent results in the first half 2013. Sales +13.8%, operating income +13.8% and net income +11.1%,

    2013, July 24

    Recordati: update on the execution of the share buy-back program

    2013, July 24

    Recordati acquires the Tunisian pharmaceutical company Opalia Pharma,

    2013, July 3

    Recordati: update on the execution of the share buy-back program

    2013, June 24

    Recordati: update on the execution of the share buy-back program

    2013, June 15

    Arrigo Recordati International Prize for Scientific Research awarded to Filippo Crea,

    2013, June 14

    Recordati: update on the execution of the share buy-back program

    2013, June 6

    Recordati: update on the execution of the share buy-back program

    2013, May 29

    Recordati: update on the execution of the share buy-back program

    2013, May 21

    Recordati: update on the execution of the share buy-back program

    2013, May 10

    Notice of filing of First Quarter 2013,

    2013-05-09 12:01

    Recordati: initiates a share buy-back program,

    2013, May 9

    Recordati: significant sales and earnings growth in the first quarter 2013 (sales +11.4%, net income +11.8%) thanks to the international business (+16.1%),

    2013, May 7

    Recordati: Public disclosure compliance - Minutes SHGM 17.4.2013

    2013, April 18

    Notice of 2012 final dividend payment,

    2013, April 17

    Recordati: shareholders approve the 2012 accounts. Dividend € 0.30 per share,

    2013, March 22

    Recordati: public disclosure compliance - Publication Remuneration report

    2013, March 15

    Recordat: public disclosure compliance – Publications of the Directors’ reports

    2013, March 15

    Shareholders' Meeting Call Notice,

    2013, March 15

    Shareholders' Meeting Call Notice,

    2013, March 14

    Recordati: Board approves a supplement to the agenda of the annual meeting of shareholders

    2013, March 14

    Recordati: public disclosure compliance

    2013, March 8

    Notice of filing of the 2012 Annual Report,

    2013, March 7

    Recordati: Board approves the 2012 accounts. Revenue € 828.3 million (+8.7%), operating income € 167.0 million (+2.1%), net income € 118.5 million (+1.8%). 2012 dividend € 0.30,

    2013, February 12

    Recordati: positive preliminary 2012 results. Sales +8.7%, EBIT +2.1%, net income +1.8%. A productive year for investments,

    2013-02-04 08:35

    Recordati to meet with the financial community and specialized press in Milan,

    2013, January 31

    Recordati: update on the execution of the share buy-back program

    2013, January 21

    Recordati finalizes its acquisition of a portfolio of products in the USA

    2012, May 8

    Recordati: good first quarter 2012 results (revenue +11.0%, net income +7.5%) thanks to the growth of the international business (+14.5%),

In Partenza Recordati.com

Stai per lasciare recordati.com per accedere al sito dedicato alle carriere di Recordati

Leaving Recordati.com

You are now leaving recordati.com to enter Recordati’s dedicated career site

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.